682 related articles for article (PubMed ID: 19543061)
21. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection.
Jordan SC; Vo AA; Toyoda M; Tyan D; Nast CC
Pediatr Transplant; 2005 Apr; 9(2):155-61. PubMed ID: 15787786
[TBL] [Abstract][Full Text] [Related]
22. C4d-positive interacinar capillaries correlates with donor-specific antibody-mediated rejection in pancreas allografts.
Torrealba JR; Samaniego M; Pascual J; Becker Y; Pirsch J; Sollinger H; Odorico J
Transplantation; 2008 Dec; 86(12):1849-56. PubMed ID: 19104433
[TBL] [Abstract][Full Text] [Related]
23. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
[TBL] [Abstract][Full Text] [Related]
24. Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients.
Aguilera I; Alvarez-Marquez A; Gentil MA; Fernandez-Alonso J; Fijo J; Saez C; Wichmann I; Nuñez-Roldan A
Nephrol Dial Transplant; 2008 Jul; 23(7):2393-8. PubMed ID: 18308775
[TBL] [Abstract][Full Text] [Related]
25. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
[TBL] [Abstract][Full Text] [Related]
26. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients.
Akalin E; Ames S; Sehgal V; Fotino M; Daly L; Murphy B; Bromberg JS
Transplantation; 2003 Nov; 76(10):1444-7. PubMed ID: 14657683
[TBL] [Abstract][Full Text] [Related]
27. Posttransplant immunosuppression in highly sensitized patients.
Akalin E
Contrib Nephrol; 2009; 162():27-34. PubMed ID: 19001811
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and treatment of acute humoral kidney allograft rejection.
Gomes AM; Pedroso S; Martins LS; Malheiro J; Viscayno JR; Santos J; Dias L; Henriques AC; Sarmento AM; Cabrita A
Transplant Proc; 2009 Apr; 41(3):855-8. PubMed ID: 19376371
[TBL] [Abstract][Full Text] [Related]
30. C4d-positive renal transplants: single-center clinical outcomes.
Ciszek M; Ptasińska AP; Durlik M; Paczek L
Clin Transpl; 2006; ():405-12. PubMed ID: 18365397
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection.
Rocha PN; Butterly DW; Greenberg A; Reddan DN; Tuttle-Newhall J; Collins BH; Kuo PC; Reinsmoen N; Fields T; Howell DN; Smith SR
Transplantation; 2003 May; 75(9):1490-5. PubMed ID: 12792502
[TBL] [Abstract][Full Text] [Related]
32. Acute antibody-mediated rejection after ABO-incompatible kidney transplantation treated successfully with antigen-specific immunoadsorption.
Just SA; Marcussen N; Sprogøe U; Koefoed-Nielsen P; Bistrup C
Nephrol Dial Transplant; 2010 Jan; 25(1):310-3. PubMed ID: 19820002
[TBL] [Abstract][Full Text] [Related]
33. Blood group Lewis alloantibodies cause antibody-mediated rejection in renal transplant recipients.
Boratyńska M; Banasik M; Hałoń A; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2711-4. PubMed ID: 18021965
[TBL] [Abstract][Full Text] [Related]
34. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
[TBL] [Abstract][Full Text] [Related]
35. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients.
Jordan SC; Peng A; Vo AA
Contrib Nephrol; 2009; 162():13-26. PubMed ID: 19001810
[TBL] [Abstract][Full Text] [Related]
37. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.
Loupy A; Suberbielle-Boissel C; Zuber J; Anglicheau D; Timsit MO; Martinez F; Thervet E; Bruneval P; Charron D; Hill GS; Nochy D; Legendre C
Transplantation; 2010 Jun; 89(11):1403-10. PubMed ID: 20386362
[TBL] [Abstract][Full Text] [Related]
38. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
39. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment.
Stegall MD; Gloor JM
Curr Opin Organ Transplant; 2010 Feb; 15(1):8-10. PubMed ID: 19890210
[TBL] [Abstract][Full Text] [Related]
40. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
